<DOC>
	<DOCNO>NCT01188187</DOCNO>
	<brief_summary>This Phase 3 study design confirm add custirsen standard first-line docetaxel/prednisone treatment slow tumor progression enhance survival outcome compare standard first-line docetaxel/prednisone treatment alone . This randomized , open-label , multicenter , international trial . Treatment consist docetaxel/prednisone/custirsen vs. docetaxel/prednisone . A total least 1000 patient randomize . Patients randomly assign equal probability two arm .</brief_summary>
	<brief_title>Comparison Docetaxel/Prednisone Docetaxel/Prednisone Combination With OGX-011 Men With Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Inclusion Criteria Age ≥ 18 year date consent . Histological cytological diagnosis adenocarcinoma prostate . Metastatic disease chest , abdominal , pelvic CT and/or bone scan . Systemic chemotherapy indicate due progression androgen ablative therapy define : 1 . Progressive measurable disease : least 20 % increase sum long diameter measurable lesion small sum observe appearance one new lesion assess CT scan hormone ablation treatment . Measurable lesion nodal visceral softtissue lesion nodal lesion ≥ 20 mm diameter visceral/softtissue lesion ≥ 10 mm diameter ( see Section 6.3.1.1 ) . OR 2 . Bone Scan Progression : appearance 2 new lesion bone scan hormone ablation treatment . OR 3 . Increasing serum prostatespecific antigen ( PSA ) level : Two consecutive increase PSA level document previous reference value obtain least one week apart require . If third PSA value less second , additional fourth test confirm rise PSA acceptable . A minimum start value 5.0 ng/mL require study randomization . Baseline laboratory value state : 1 . Creatinine ≤ 1.5 x upper limit normal ( ULN ) . 2 . Bilirubin ≤ 1.1 x ULN ( unless elevate secondary condition Gilbert 's disease ) . 3 . Serum glutamic oxaloacetic transaminase ( SGOT ) serum glutamic pyruvic transaminase ( SGPT ) ≤ 1.5 x ULN . 4 . Castrate serum testosterone level ( &lt; 50 ng/dLor &lt; 1.7 nmol/L ) . Must willing continue primary androgen suppression gonadotropinreleasing hormone ( GnRH ) analogues ( either agonist antagonist ) throughout study , unless treat bilateral orchiectomy . Adequate bone marrow function define screen absolute neutrophil count ( ANC ) ≥ 1.5 x 10^9 cell /L platelet count ≥ 100 x 10^9 /L . Karnofsky score ≥ 70 % ( see Appendix 17.2 ) . At least 28 day pass since complete radiotherapy ( exception radiotherapy : least 7 day since complete single fraction ≤ 800 centigray ( cGy ) restrict field limitedfield radiotherapy nonmarrow bear area extremity orbit ) time randomization . At least 4 week pass since receive investigational agent time randomization . Has recover therapyrelated toxicity ≤ grade 2 , ( except alopecia , anemia sign symptom androgen deprivation therapy ) . Patient must willing add , delete change current bisphosphonate denosumab usage throughout study treatment assure adverse event reporting confound change bisphosphonate denosumab usage ( unless withdrawn change result bisphosphonate denosumab associate toxicity ) . Patients receive 10 mg prednisone per day ( steroid equivalent ) screening must willing dose reduce 10 mg prednisone per day least 7 day prior randomization maintain throughout study treatment . Written informed consent must obtain prior protocolspecific procedure perform . Exclusion Criteria Received cytotoxic chemotherapy treatment prostate cancer . Received cycling , intermittent continuous hormonal treatment 28 day prior randomization exception continuous GnRH analogue require Inclusion Criteria # 6 . Participated prior clinical study evaluate custirsen . History current document brain metastasis carcinomatous meningitis , treat untreated . ( Brain image asymptomatic patient require . ) Current symptomatic cord compression require surgery radiation therapy . ( Once successfully treat progression , patient eligible study . ) Active second malignancy ( except nonmelanomatous skin superficial bladder cancer ) define require anticancer therapy high risk recurrence study . Active second malignancy ( except non melanomatous skin superficial bladder cancer ) define require cancer therapy high risk reoccurrence study Uncontrolled medical condition heart failure , myocardial infarction , uncontrolled hypertension , stroke treatment major active infection within 3 month randomization , well significant concurrent medical illness opinion Investigator would preclude protocol therapy . Planned concomitant participation another clinical trial experimental agent , vaccine , device . Concomitant participation observational study acceptable .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>custirsen sodium</keyword>
	<keyword>prostate cancer</keyword>
	<keyword>overall survival</keyword>
	<keyword>Metastatic Castrate Resistant Prostate Cancer</keyword>
</DOC>